Vulvovaginal human papillomavirus infections: clinical implications and management.
The past 2 decades have witnessed an alarming increase in the incidence of human papillomavirus infections. Clinically evident cases represent only a small portion of the infected population, because millions of people have subclinical or latent infection. Human papillomavirus infection is recognized as a precursor to malignancy. Thus it is important to treat clinically evident infection. Treatment is complicated by the ability of the virus to establish latent infection and the lack of an effective antiviral agent. At present treatment is limited to the destruction of obvious and intraepithelial lesions.
Hatch
K D
KD
Department of Obstetrics and Gynecology, University of Arizona, Tucson 85724.
D000328:Adult; D003218:Condylomata Acuminata / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D053685:Laser Therapy; D009364:Neoplasm Recurrence, Local; D027383:Papillomaviridae / Q000472:pathogenicity*; D014238:Trichloroacetic Acid / Q000627:therapeutic use; D014412:Tumor Virus Infections / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D016898:Interferon-alpha; D014238:Trichloroacetic Acid; D003999:Dichloroacetic Acid